Part 3/7:
Jeff Fischer, a financial analyst, explained that Gilead's situation resembles the decline faced by tech giants like Apple with the iPhone—after an initial growth phase, revenue plateaus and even dips. Despite having more hepatitis C patients last quarter, the revenue decreased. This is primarily due to rising competition and the company's need to offer discounts and price concessions to sustain market share, which directly impacts profit margins.